Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.

Jamal-Hanjani, Mariam, Hackshaw, Alan, Ngai, Yenting, Shaw, Jacqueline, Dive, Caroline, Quezada, Sergio, Middleton, Gary, de Bruin, Elza, Le Quesne, John, Shafi, Seema, Falzon, Mary, Horswell, Stuart, Blackhall, Fiona, Khan, Iftekhar, Janes, Sam, Nicolson, Marianne, Lawrence, David, Forster, Martin, Fennell, Dean, Lee, Siow-Ming, Lester, Jason, Kerr, Keith, Muller, Salli, Iles, Natasha, Smith, Sean, Murugaesu, Nirupa, Mitter, Richard, Salm, Max, Stuart, Aengus, Matthews, Nik, Adams, Haydn, Ahmad, Tanya, Attanoos, Richard, Bennett, Jonathan, Birkbak, Nicolai Juul, Booton, Richard, Brady, Ged, Buchan, Keith, Capitano, Arrigo, Chetty, Mahendran, Cobbold, Mark, Crosbie, Philip, Davies, Helen, Denison, Alan, Djearman, Madhav, Goldman, Jacki, Haswell, Tom, Joseph, Leena, Kornaszewska, Malgorzata, Krebs, Matthew, Langman, Gerald, MacKenzie, Mairead, Millar, Joy, Morgan, Bruno, Naidu, Babu, Nonaka, Daisuke, Peggs, Karl, Pritchard, Catrin, Remmen, Hardy, Rowan, Andrew, Shah, Rajesh, Smith, Elaine, Summers, Yvonne, Taylor, Magali, Veeriah, Selvaraju, Waller, David, Wilcox, Ben, Wilcox, Maggie, Woolhouse, Ian, McGranahan, Nicholas and Swanton, Charles (2014) Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS biology, 12 (7). e1001906. ISSN 1545-7885.

Text (PDF file format)
http___www.plosbiology.org_article_fetchObject.action_uri=info_doi_10.1371_journal.pbio.pdf - Published Version
Available under License Creative Commons Attribution.

Download (717kB) | Preview
Official URL:


The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.

Item Type: Article
Subjects: QZ Pathology. Oncology
WF Respiratory system. Respiratory medicine
Divisions: Clinical Support > Pathology
Clinical Support > Radiology
Planned IP Care > Oncology and Clinical Haematology
Planned IP Care > Thoracic Surgery
Related URLs:
Depositing User: Mrs Yolande Brookes
Date Deposited: 30 Apr 2015 12:32
Last Modified: 30 Apr 2015 12:32

Actions (login required)

View Item View Item